MUC1 and non-small cell lung carcinoma: In a phase 2b/3 trial for advanced non-small-cell lung cancer, TG4010 (a modified vaccinia Ankara expressing MUC1) plus chemotherapy showed a significant improvement in progression-free survival compared to a placebo plus chemotherapy [17].